FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036953628> ?p ?o ?g. }

• W2036953628 endingPage "4414" @default.
• W2036953628 startingPage "4407" @default.
• W2036953628 abstract "Cisplatin-containing chemotherapy is the standard of care for patients with locally advanced and metastatic transitional cell carcinoma of the urothelium. The response rate is approximately 50% and tumor-derived molecular prognostic markers are desirable for improved estimation of response and survival.Affymetrix GeneChip expression profiling was carried out using tumor material from 30 patients. A set of genes with an expression highly correlated to survival time after chemotherapy was identified. Two genes were selected for validation by immunohistochemistry in an independent material of 124 patients receiving cisplatin-containing therapy.Fifty-five differentially expressed genes correlated significantly to survival time. Two of the protein products (emmprin and survivin) were validated using immunohistochemistry. Multivariate analysis identified emmprin expression (hazard ratio, 2.23; P < 0.0001) and survivin expression (hazard ratio, 2.46; P < 0.0001) as independent prognostic markers for poor outcome, together with the presence of visceral metastases (hazard ratio, 2.62; P < 0.0001). In the clinical good prognostic group of patients without visceral metastases, both markers showed significant discriminating power as supplemental risk factors (P < 0.0001). Within this group of patients, the subgroups of patients with no positive, one positive, or two positive immunohistochemistry scores (emmprin and survivin) had estimated 5-year survival rates of 44.0%, 21.1%, and 0%, respectively. Response to chemotherapy could also be predicted with an odds ratio of 4.41 (95% confidence interval, 1.91-10.1) and 2.48 (95% confidence interval, 1.1-5.5) for emmprin and survivin, respectively.Emmprin and survivin proteins were identified as strong independent prognostic factors for response and survival after cisplatin-containing chemotherapy in patients with advanced bladder cancer." @default.
• W2036953628 created "2016-06-24" @default.
• W2036953628 creator A5007280131 @default.
• W2036953628 creator A5018966571 @default.
• W2036953628 creator A5025677771 @default.
• W2036953628 creator A5025776675 @default.
• W2036953628 creator A5027336843 @default.
• W2036953628 creator A5028534654 @default.
• W2036953628 creator A5050758135 @default.
• W2036953628 creator A5053045551 @default.
• W2036953628 creator A5059666085 @default.
• W2036953628 creator A5073578961 @default.
• W2036953628 creator A5091593545 @default.
• W2036953628 date "2007-08-01" @default.
• W2036953628 modified "2023-10-02" @default.
• W2036953628 title "Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer" @default.
• W2036953628 cites W17855875 @default.
• W2036953628 cites W1857682357 @default.
• W2036953628 cites W1966315696 @default.
• W2036953628 cites W1978577165 @default.
• W2036953628 cites W1982250680 @default.
• W2036953628 cites W1985585396 @default.
• W2036953628 cites W1994017228 @default.
• W2036953628 cites W1995013627 @default.
• W2036953628 cites W1996937427 @default.
• W2036953628 cites W2000416122 @default.
• W2036953628 cites W2000771269 @default.
• W2036953628 cites W2030328915 @default.
• W2036953628 cites W2033681375 @default.
• W2036953628 cites W2034417099 @default.
• W2036953628 cites W2042289233 @default.
• W2036953628 cites W2044021534 @default.
• W2036953628 cites W2057084845 @default.
• W2036953628 cites W2066787077 @default.
• W2036953628 cites W2074755242 @default.
• W2036953628 cites W2075732859 @default.
• W2036953628 cites W2078878344 @default.
• W2036953628 cites W2081496297 @default.
• W2036953628 cites W2083900400 @default.
• W2036953628 cites W2087512526 @default.
• W2036953628 cites W2095571145 @default.
• W2036953628 cites W2099273077 @default.
• W2036953628 cites W2101562875 @default.
• W2036953628 cites W2103257412 @default.
• W2036953628 cites W2105631098 @default.
• W2036953628 cites W2117058881 @default.
• W2036953628 cites W2125396123 @default.
• W2036953628 cites W2133463872 @default.
• W2036953628 cites W2133734904 @default.
• W2036953628 cites W2138178697 @default.
• W2036953628 cites W2146356730 @default.
• W2036953628 cites W2151090276 @default.
• W2036953628 cites W2153562609 @default.
• W2036953628 cites W2153899562 @default.
• W2036953628 cites W2159602607 @default.
• W2036953628 cites W2163453798 @default.
• W2036953628 cites W2170989872 @default.
• W2036953628 cites W4233640630 @default.
• W2036953628 cites W4246376116 @default.
• W2036953628 cites W4294107304 @default.
• W2036953628 doi "https://doi.org/10.1158/1078-0432.ccr-07-0109" @default.
• W2036953628 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17671123" @default.
• W2036953628 hasPublicationYear "2007" @default.
• W2036953628 type Work @default.
• W2036953628 sameAs 2036953628 @default.
• W2036953628 citedByCount "193" @default.
• W2036953628 countsByYear W20369536282012 @default.
• W2036953628 countsByYear W20369536282013 @default.
• W2036953628 countsByYear W20369536282014 @default.
• W2036953628 countsByYear W20369536282015 @default.
• W2036953628 countsByYear W20369536282016 @default.
• W2036953628 countsByYear W20369536282017 @default.
• W2036953628 countsByYear W20369536282018 @default.
• W2036953628 countsByYear W20369536282019 @default.
• W2036953628 countsByYear W20369536282020 @default.
• W2036953628 countsByYear W20369536282021 @default.
• W2036953628 countsByYear W20369536282022 @default.
• W2036953628 countsByYear W20369536282023 @default.
• W2036953628 crossrefType "journal-article" @default.
• W2036953628 hasAuthorship W2036953628A5007280131 @default.
• W2036953628 hasAuthorship W2036953628A5018966571 @default.
• W2036953628 hasAuthorship W2036953628A5025677771 @default.
• W2036953628 hasAuthorship W2036953628A5025776675 @default.
• W2036953628 hasAuthorship W2036953628A5027336843 @default.
• W2036953628 hasAuthorship W2036953628A5028534654 @default.
• W2036953628 hasAuthorship W2036953628A5050758135 @default.
• W2036953628 hasAuthorship W2036953628A5053045551 @default.
• W2036953628 hasAuthorship W2036953628A5059666085 @default.
• W2036953628 hasAuthorship W2036953628A5073578961 @default.
• W2036953628 hasAuthorship W2036953628A5091593545 @default.
• W2036953628 hasBestOaLocation W20369536281 @default.
• W2036953628 hasConcept C121608353 @default.
• W2036953628 hasConcept C126322002 @default.
• W2036953628 hasConcept C142724271 @default.
• W2036953628 hasConcept C143998085 @default.
• W2036953628 hasConcept C156957248 @default.
• W2036953628 hasConcept C204232928 @default.
• W2036953628 hasConcept C207103383 @default.

• next